LifeStance Appoints Dave Bourdon as CEO; Ken Burdick Named Executive Chairman
LifeStance Health Group (Nasdaq: LFST) announced significant leadership changes, with Dave Bourdon appointed as the new CEO effective March 3, succeeding Ken Burdick who will transition to Executive Chairman. Bourdon, who joined as CFO in 2022, brings over two decades of healthcare and mental health industry experience.
Ryan McGroarty, with 25 years of healthcare experience including 15 years in CFO roles, will become the new Chief Financial Officer effective March 17. Under Burdick's leadership since September 2022, LifeStance has met or exceeded expectations for nine consecutive quarters.
Bourdon previously served as CFO of Magellan Health and held positions at Cigna, while McGroarty comes from Help at Home where he served as CFO and previously held multiple CFO roles at Cigna.
LifeStance Health Group (Nasdaq: LFST) ha annunciato importanti cambiamenti nella leadership, con Dave Bourdon nominato nuovo CEO a partire dal 3 marzo, succedendo a Ken Burdick che passerà a ricoprire il ruolo di Presidente Esecutivo. Bourdon, che è entrato come CFO nel 2022, porta con sé oltre due decenni di esperienza nel settore sanitario e della salute mentale.
Ryan McGroarty, con 25 anni di esperienza nel settore sanitario, di cui 15 anni in ruoli di CFO, diventerà il nuovo Direttore Finanziario a partire dal 17 marzo. Sotto la guida di Burdick, dal settembre 2022, LifeStance ha soddisfatto o superato le aspettative per nove trimestri consecutivi.
Bourdon ha precedentemente ricoperto il ruolo di CFO di Magellan Health e ha avuto posizioni in Cigna, mentre McGroarty proviene da Help at Home dove ha ricoperto il ruolo di CFO e ha precedentemente ricoperto molteplici ruoli di CFO in Cigna.
LifeStance Health Group (Nasdaq: LFST) anunció cambios significativos en su liderazgo, con Dave Bourdon nombrado como nuevo CEO a partir del 3 de marzo, sucediendo a Ken Burdick, quien pasará a ser Presidente Ejecutivo. Bourdon, quien se unió como CFO en 2022, aporta más de dos décadas de experiencia en la industria de la salud y la salud mental.
Ryan McGroarty, con 25 años de experiencia en el sector salud, incluyendo 15 años en roles de CFO, se convertirá en el nuevo Director Financiero a partir del 17 de marzo. Bajo el liderazgo de Burdick desde septiembre de 2022, LifeStance ha cumplido o superado las expectativas durante nueve trimestres consecutivos.
Bourdon anteriormente fue CFO de Magellan Health y ocupó cargos en Cigna, mientras que McGroarty proviene de Help at Home, donde se desempeñó como CFO y anteriormente ocupó múltiples roles de CFO en Cigna.
라이프스턴스 헬스 그룹 (Nasdaq: LFST)는 중요한 리더십 변화를 발표했으며, 데이브 보르돈이 3월 3일부터 새로운 CEO로 임명되었고, 켄 버디크는 집행 의장직으로 전환됩니다. 2022년에 CFO로 합류한 보르돈은 20년 이상의 의료 및 정신 건강 산업 경험을 가지고 있습니다.
라이언 맥그로어티는 25년의 의료 경험을 가지고 있으며, 그 중 15년은 CFO 역할을 맡아 새로운 재무 책임자로 3월 17일부터 임명됩니다. 2022년 9월 이후 버디크의 지도 아래, 라이프스턴스는 9분기 연속으로 기대치를 충족하거나 초과했습니다.
보르돈은 이전에 마젤란 헬스의 CFO로 재직했으며, 시그나에서 여러 직책을 맡았고, 맥그로어티는 헬프 앳 홈에서 CFO로 근무했으며 이전에 시그나에서 여러 CFO 역할을 맡았습니다.
LifeStance Health Group (Nasdaq: LFST) a annoncé d'importants changements au sein de sa direction, avec Dave Bourdon nommé nouveau PDG à compter du 3 mars, succédant à Ken Burdick qui deviendra Président Exécutif. Bourdon, qui a rejoint l'entreprise en tant que CFO en 2022, apporte plus de deux décennies d'expérience dans le secteur de la santé et de la santé mentale.
Ryan McGroarty, avec 25 ans d'expérience dans le secteur de la santé, dont 15 ans dans des rôles de CFO, deviendra le nouveau Directeur Financier à compter du 17 mars. Sous la direction de Burdick depuis septembre 2022, LifeStance a satisfait ou dépassé les attentes pendant neuf trimestres consécutifs.
Bourdon a précédemment été CFO de Magellan Health et a occupé des postes chez Cigna, tandis que McGroarty vient de Help at Home où il a occupé le poste de CFO et a précédemment exercé plusieurs rôles de CFO chez Cigna.
LifeStance Health Group (Nasdaq: LFST) hat bedeutende Veränderungen in der Führung angekündigt, wobei Dave Bourdon ab dem 3. März neuer CEO wird und Ken Burdick als Executive Chairman wechseln wird. Bourdon, der 2022 als CFO eingetreten ist, bringt über zwei Jahrzehnte Erfahrung in der Gesundheits- und Psychiatriebranche mit.
Ryan McGroarty, der über 25 Jahre Erfahrung im Gesundheitswesen verfügt, einschließlich 15 Jahre in CFO-Rollen, wird ab dem 17. März neuer Chief Financial Officer. Unter Burdicks Leitung seit September 2022 hat LifeStance in neun aufeinanderfolgenden Quartalen die Erwartungen erfüllt oder übertroffen.
Bourdon war zuvor CFO von Magellan Health und hatte Positionen bei Cigna inne, während McGroarty von Help at Home kommt, wo er als CFO tätig war und zuvor mehrere CFO-Rollen bei Cigna hatte.
- Consistent financial performance with 9 consecutive quarters meeting/exceeding expectations
- Internal promotion ensures leadership continuity
- New CEO brings extensive healthcare and mental health industry experience
- New CFO brings 25 years of healthcare experience including multiple CFO roles
- CEO transition period may create temporary operational uncertainty
Ryan McGroarty to Become Chief Financial Officer
"Since joining LifeStance, we've made tremendous progress fortifying our foundation and strengthening our leadership bench to ensure that we provide an exceptional patient experience in alignment with our mission," said Burdick. "Given our consistently strong operational and financial performance, I am confident that now is the right time to transition to a new CEO and believe Dave is exceptionally qualified to lead LifeStance into this exciting new chapter, while I continue to contribute to our long-term strategic direction."
Burdick continued, "Having worked closely with Dave, I know that this continuity in leadership will help LifeStance continue its strong momentum over the long term. Dave's strategic thinking, deep health care experience and collaborative relationships with both internal teams and external stakeholders have helped us deliver consistently strong financial and operational performance over the last two years. His passion for executing on our mission to expand access to high-quality, affordable mental health care, demonstrated commitment to our core values and patient-first mindset make him the right leader to guide LifeStance into the future."
Bourdon said, "I am honored to serve as LifeStance's next CEO and have the opportunity to lead such an incredibly dedicated and talented team as we continue to focus on transforming mental health care and expanding access to communities across the country. I'm proud of the strong progress we've achieved over the last two years and look forward to working together to drive clinical and operational excellence, exceptional service for our patients and, in turn, profitable growth for shareholders. It has been a privilege to work alongside Ken, and I look forward to our continued collaboration as Ken steps into the Executive Chair role and we build on our positive momentum in the market."
Bourdon has served as CFO of LifeStance since November 2022. He has more than two decades of experience in the health care and mental health industries in both financial and operational roles. He previously served as CFO of Magellan Health, a leader in behavioral health and pharmacy management, and held multiple positions at Cigna. He began his career serving for eight years with the United States Coast Guard.
Burdick has served as CEO and Chairman since September 2022 and has held numerous executive and leadership roles over the course of his 45-year career in health care. Under his leadership, LifeStance has delivered consistent financial performance, meeting or exceeding expectations in each of the last nine quarters. Before joining LifeStance, he served as the Executive Vice President of Markets and Products at Centene Corporation, before retiring in 2021. Previously, he was the Chief Executive Officer of WellCare Health Plans, Inc., where he led the company in its mission to provide quality, cost-effective health care for Medicare and Medicaid beneficiaries.
McGroarty previously served as Chief Financial Officer of Help at Home, the leading national provider of innovative, high-quality, relationship-based, in-home care services for seniors and people living with disabilities. Prior to Help at Home, McGroarty served in multiple CFO roles at Cigna, most recently as Chief Financial Officer of Government Business. He has extensive experience in government and commercial programs, delivery of health care and population and value-based solutions.
As previously announced, LifeStance will hold a conference call today, February 27 at 8:30 a.m. Eastern Time to discuss the Company's fourth quarter and full year 2024 results.
About LifeStance Health
Founded in 2017, LifeStance (Nasdaq: LFST) is reimagining mental health. We are one of the nation's largest providers of virtual and in-person outpatient mental healthcare for children, adolescents and adults experiencing a variety of mental health conditions. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable, and personalized mental healthcare. LifeStance and its supported practices employ approximately 7,400 psychiatrists, advanced practice nurses, psychologists and therapists and operate across 33 states and more than 550 centers. To learn more, please visit www.LifeStance.com.
Forward-Looking Statements
Statements in this press release that express a belief, expectation or intention, as well as those that are not historical fact, are forward-looking statements. These statements include, but are not limited to, statements with respect to the Company's business plans and objectives and other statements contained in this press release that are not historical facts. When used in this press release, words such as "may," "will," "should," "could," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "seek" and similar expressions as they relate to us are intended to identify forward-looking statements. They involve a number of risks and uncertainties that may cause actual events and results to differ materially from such forward-looking statements. These risks and uncertainties include, but are not limited to: if reimbursement rates by third-party payors are reduced or if third-party payors otherwise restrain our ability to obtain or deliver care to patients, our business could be harmed; we may not grow at the rates we historically have achieved or at all, even if our key metrics may imply future growth, including if we are unable to successfully execute on our growth initiatives and business strategies; if we fail to manage our growth effectively, our expenses could increase more than expected, our revenue may not increase proportionally or at all, and we may be unable to execute on our business strategy; our ability to recruit new clinicians and retain existing clinicians; we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur penalties or be required to make significant changes to our operations or experience adverse publicity, which could have a material adverse effect on our business, results of operations and financial condition; we are dependent on our relationships with supported practices, which we do not own, to provide healthcare services, and our business would be harmed if those relationships were disrupted or if our arrangements with these entities became subject to legal challenges; we operate in a competitive industry, and if we are not able to compete effectively, our business and financial condition would be harmed; the impact of health care reform legislation and other changes in the healthcare industry and in health care spending on us is currently unknown, but may harm our business; if our or our vendors' security measures fail or are breached and unauthorized access to our employees', patients' or partners' data is obtained, our systems may be perceived as insecure, we may incur significant liabilities, including through private litigation or regulatory action, our reputation may be harmed, and we could lose patients and partners; our business depends on our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems; our existing indebtedness could adversely affect our business and growth prospects; and other risks and uncertainties set forth under "Risk Factors" included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent filings made with the Securities and Exchange Commission. LifeStance does not undertake to update any forward-looking statements made in this press release to reflect any change in management's expectations or any change in the assumptions or circumstances on which such statements are based, except as otherwise required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lifestance-appoints-dave-bourdon-as-ceo-ken-burdick-named-executive-chairman-302386817.html
SOURCE LifeStance Health
FAQ
When will Dave Bourdon start as LifeStance (LFST) CEO?
What is Ken Burdick's new role at LifeStance (LFST)?
How has LifeStance (LFST) performed under Ken Burdick's leadership?
Who is the new CFO of LifeStance (LFST) and when does he start?
What is Dave Bourdon's background before becoming LifeStance (LFST) CEO?
